Stoke Therapeutics Inc.
- Address
- 45 Wiggins Avenue
Sponsor Overview
Specializations
Neurology and epilepsy
Clinical research in Dravet syndrome with attention to major motor seizures, including hemiclonic seizures, focal seizures with motor signs, focal to bilateral tonic-clonic seizures, generalized tonic-clonic seizures, tonic seizures, tonic-atonic drop attacks, and bilateral clonic seizures.
- Seizure frequency
- Motor seizure control
- Dravet syndrome
Research activity in this area is centered on therapeutic options for severe childhood-onset epileptic encephalopathy.
Ophthalmology and optic nerve disorders
Studies in autosomal dominant optic atrophy focus on visual pathway disease and inherited optic nerve degeneration, with interest in treatment-related safety and systemic exposure.
- Autosomal dominant optic atrophy
- Optic nerve degeneration
- Visual impairment
The research profile includes conditions affecting central visual function and inherited neuro-ophthalmic disease.
Genetic medicine and rare disease therapeutics
The sponsor’s trial portfolio reflects work in genetic disorders with monogenic disease mechanisms, including neurologic and ophthalmic indications.
- Inherited disease
- Monogenic disorders
- Rare disease treatment
Current research spans conditions where targeted therapeutic development is directed at underlying genetic causation.
Clinical pharmacology and tolerability assessment
Ongoing studies include evaluation of safety, tolerability, and systemic exposure in both neurologic and ophthalmic patient populations.
- Safety monitoring
- Tolerability
- Exposure assessment
This area links therapeutic development with clinical characterization of treatment effects in central nervous system and eye disease settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of STK-002 in Autosomal Dominant Optic Atrophy Patients |  Austria Denmark Germany Italy | Recruiting |
| Phase 3 Double-Blind Study of Zorevunersen Sodium in Reducing Major Motor Seizure Frequency in Dravet Syndrome Patients |  France Germany Italy Poland Spain Sweden | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 25 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial165 other sponsors
- 2.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
25 centres- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Viale Gaetano Pieraccini 24, 50139 Florence
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Largo Francesco Vito 1, 00168 Rome
- Address
- Theodor-Stern-Kai 7, 60590 Frankfurt
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Stoke Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.